Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 548 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Antiviral Drug Clear all
Completed Phase 2 Interventional

Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

NCT00298350
View directory record Official record
Conditions
HIV, HIV-1, Human Immunodeficiency Virus
Interventions
GS-9137 - A Novel HIV-1 Integrase Inhibitor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
52
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Oct 4, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients

NCT00002363
View directory record Official record
Conditions
HIV Infections
Interventions
Peptide Construction 3, Synthetic
Drug
Lead sponsor
Columbia Research Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 4, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy

NCT02607735
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF/VEL/VOX, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
43
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 4, 2026, 10:57 AM EDT
Enrolling by invitation Phase 2 Interventional

Effects of Antiviral Therapies on Epstein-Barr Virus Replication

NCT05957913
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Truvada (tenofovir/emtricitabine)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 4, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

NCT00703586
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 4, 2026, 10:57 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

NCT02441283
View directory record Official record
Conditions
Hepatitis C
Interventions
ABT-493, ABT-530
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
20
States / cities
Dothan, Alabama • Bakersfield, California • Coronado, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 4, 2026, 10:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

GS-7977 With Ribavirin for Hepatitis C (SPARE)

NCT01441180
View directory record Official record
Conditions
Hepatitis C
Interventions
GS7977, RBV
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2014 · Synced Oct 4, 2026, 10:57 AM EDT
Completed Not applicable Interventional

A Study to Evaluate the Ability of TNFR:Fc to Decrease the Amount of IL-6 (Interleukin-6) and TNF-alpha (Tumor Necrosis Factor) in HIV-Infected Patients

NCT00001116
View directory record Official record
Conditions
HIV Infections
Interventions
Tumor Necrosis Factor soluble receptor-immunoadhesin complex
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
3
States / cities
Honolulu, Hawaii • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 4, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection

NCT01079806
View directory record Official record
Conditions
Chronic Hepatitis B Virus, Pediatric
Interventions
Entecavir, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
2 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
15
States / cities
San Francisco, California • Hartford, Connecticut • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 4, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

NCT02639247
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL/VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
43
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 4, 2026, 10:57 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

NCT05487040
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332 (nirmatrelvir)/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
52
States / cities
Huntsville, Alabama • Granada Hills, California • Inglewood, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 4, 2026, 10:57 AM EDT
Terminated Phase 1 Interventional

Study of GS-1219 in Participants With HIV-1

NCT07115368
View directory record Official record
Conditions
HIV-1-infection
Interventions
GS-1219, BVY, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 4, 2026, 10:57 AM EDT
Completed Phase 2 Interventional

A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

NCT00002364
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Greenbrae, California • Los Angeles, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 4, 2026, 10:57 AM EDT
Terminated Phase 3 Interventional Results available

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

NCT01821963
View directory record Official record
Conditions
Infection
Interventions
Pegylated Interferon Alfa 2a, Ribavirin, Telaprevir
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 69 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 4, 2026, 10:57 AM EDT
Completed Phase 4 Interventional

Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients

NCT00722332
View directory record Official record
Conditions
Hepatitis B, Liver Transplantation
Interventions
HepaGam B
Biological
Lead sponsor
Cangene Corporation
Industry
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 4, 2026, 10:57 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II

NCT07513623
View directory record Official record
Conditions
Cytomegalovirus (CMV), Anterior Uveitis, Infectious Uveitis, CMV Infection
Interventions
Valganciclovir, Ganciclovir (GCV), Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 4, 2026, 10:57 AM EDT
Completed Phase 2 Interventional

Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy

NCT00120861
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
valopicitabine, pegylated interferon, ribavirin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Timeline
Started 2005
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Oct 4, 2026, 10:57 AM EDT
Completed Phase 4 Interventional

Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis

NCT00000894
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Cidofovir, Probenecid, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 4, 2026, 10:57 AM EDT
Completed Phase 3 Interventional

A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months

NCT00000841
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
1,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
85
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 4, 2026, 10:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle

NCT04141930
View directory record Official record
Conditions
Influenza, Respiratory Viral Infection
Interventions
Baloxavir Marboxil
Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Months and older
Enrollment
481 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 4, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19

NCT04575038
View directory record Official record
Conditions
COVID-19 Infection
Interventions
Brequinar, Placebo
Drug
Lead sponsor
Clear Creek Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
14
States / cities
Homewood, Alabama • Long Beach, California • Doral, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 4, 2026, 10:57 AM EDT
Completed No phase listed Observational

Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor

NCT00001826
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 4, 2026, 10:57 AM EDT
Completed Phase 2 Interventional

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

NCT01371578
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a, ribavirin tablet
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Dothan, Alabama • Montgomery, Alabama • Beverly Hills, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 4, 2026, 10:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study of Orally Administered GS-441524 for COVID-19

NCT04859244
View directory record Official record
Conditions
COVID-19
Interventions
GS-441524
Drug
Lead sponsor
Copycat Sciences LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 4, 2026, 10:57 AM EDT